Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...

Altamira Therapeutics Provides Business Update Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy...